Jaguar Health free cash flow JAGX

Cash from operations less capital spending, by quarter and over the last twelve months, from 2014.

Jaguar Health's twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q4 FY24, it was −$7.8M.

Free cash flow over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Free cash flow	On a year earlier	Last 12 months
Q4 FY24	Dec 31, 2024	−$7.8M	n/a	n/a
Q3 FY24	Sep 30, 2024	−$6.3M	n/a	n/a
Q3 FY23	Sep 30, 2023	−$6.8M	n/a	−$32.2M
Q2 FY23	Jun 30, 2023	−$9.1M	n/a	−$34M
Q1 FY23	Mar 31, 2023	−$9.9M	n/a	n/a
Q4 FY22	Dec 31, 2022	−$6.4M	n/a	n/a
Q3 FY22	Sep 30, 2022	−$8.5M	n/a	n/a
Q4 FY21	Dec 31, 2021	−$8.9M	n/a	n/a
Q3 FY21	Sep 30, 2021	−$9.4M	n/a	n/a
Q4 FY20	Dec 31, 2020	−$4.1M	n/a	−$15.3M
Q3 FY20	Sep 30, 2020	−$2.9M	n/a	n/a
Q2 FY20	Jun 30, 2020	−$4M	n/a	n/a

Companies in Drug Manufacturers - General nearest Jaguar Health's size, closest first, today.

Company	Free cash flow yield
JAGXJaguar Health	n/m
LABTLakewood-Amedex Biotherapeutics	n/m
NXTSNexentis Technologies	n/m
DCOYDecoy Therapeutics	n/m
VBIOValion Bio	−1758.8%
SBFMSunshine Biopharma	−920.4%
ARTLArtelo Biosciences	n/m
LNAILunai Bioworks	n/m
GNPXGenprex	n/m
GOVXGeoVax Labs	−1210.1%
ONCOOnconetix	n/m
Peer median	−1210.1%